New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression.

This review focuses on matrix metalloproteinases (MMPs)-2 (gelatinase A) and -9 (gelatinase B), both of which are cancer-associated, secreted, zinc-dependent endopeptidases. Gelatinases cleave many different targets (extracellular matrix, cytokines, growth factors, chemokines and cytokine/growth factor receptors) that in turn regulate key signaling pathways in cell growth, migration, invasion, inflammation and angiogenesis. Interactions with cell surface integral membrane proteins (CD44, αVβ/αβ1/αβ2 integrins and Ku protein) can occur through the gelatinases' active site or hemopexin-like C-terminal domain. This review evaluates the recent literature on the non-enzymatic, signal transduction roles of surface-bound gelatinases and their subsequent effects on cell survival, migration and angiogenesis. Gelatinases have long been drug targets. The current status of gelatinase inhibitors as anticancer agents and their failure in the clinic is discussed in light of these new data on the gelatinases' roles as cell surface transducers - data that may lead to the design and development of novel, gelatinase-targeting inhibitors.

[1]  J. Quigley,et al.  Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. , 2010, Biochimica et biophysica acta.

[2]  L. Matrisian,et al.  The other side of MMPs: Protective roles in tumor progression , 2007, Cancer and Metastasis Reviews.

[3]  C. Muller,et al.  The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9 , 2004, The EMBO journal.

[4]  M. Muche,et al.  The alpha 2 chain of collagen type VI sequesters latent proforms of matrix-metalloproteinases and modulates their activation and activity. , 2009, Matrix biology : journal of the International Society for Matrix Biology.

[5]  C. Overall,et al.  Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. , 2010, Biochimica et biophysica acta.

[6]  Ø. Bruserud,et al.  The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. , 2010, Current medicinal chemistry.

[7]  Z. Han,et al.  Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. , 2006, Histology and histopathology.

[8]  M. Moses,et al.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Weiss,et al.  Secreted Versus Membrane-anchored Collagenases , 2009, The Journal of Biological Chemistry.

[10]  P. Poyet,et al.  Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. , 2001, Seminars in oncology.

[11]  C. Demur,et al.  Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features , 2008, Cell cycle.

[12]  M. Gujrati,et al.  MMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16(INK4a) and mitogen-activated protein kinase pathway. , 2007, Cancer research.

[13]  E. Koivunen,et al.  Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. , 2006, Blood.

[14]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[15]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[16]  T. Turpeenniemi‐Hujanen,et al.  Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. , 2005, Biochimie.

[17]  P. Bornstein,et al.  The Low Density Lipoprotein Receptor-related Protein Modulates Levels of Matrix Metalloproteinase 9 (MMP-9) by Mediating Its Cellular Catabolism* , 2001, The Journal of Biological Chemistry.

[18]  K. Conant,et al.  Matrix Metalloproteinase 1 Interacts with Neuronal Integrins and Stimulates Dephosphorylation of Akt* , 2004, Journal of Biological Chemistry.

[19]  K. Brew,et al.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.

[20]  A. Paller,et al.  Ganglioside GM3 Inhibits Matrix Metalloproteinase-9 Activation and Disrupts Its Association with Integrin* , 2003, Journal of Biological Chemistry.

[21]  L. Coussens,et al.  Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[22]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[23]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[24]  D. Sullivan,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors , 2007, Clinical Cancer Research.

[25]  C. Gahmberg,et al.  Intracellular and Cell Surface Localization of a Complex between αMβ2 Integrin and Promatrix Metalloproteinase-9 Progelatinase in Neutrophils1 , 2004, The Journal of Immunology.

[26]  L. Holubec,et al.  Biological activity and clinical implications of the matrix metalloproteinases. , 2008, Anticancer research.

[27]  Y Ikawa,et al.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Overall,et al.  Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical , 2005 .

[29]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[30]  B. Cauwe,et al.  The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases , 2007, Critical reviews in biochemistry and molecular biology.

[31]  B. Bauvois,et al.  Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons , 2002, Leukemia.

[32]  Masanori Hangai,et al.  Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. , 2002, The American journal of pathology.

[33]  J. S. Rao,et al.  MMP‐2 alters VEGF expression via αVβ3 integrin‐mediated PI3K/AKT signaling in A549 lung cancer cells , 2009, International journal of cancer.

[34]  C. López-Otín,et al.  Emerging roles of proteases in tumour suppression , 2007, Nature Reviews Cancer.

[35]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[36]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.

[37]  J. Becker,et al.  Role of matrix metalloproteinases in melanoma cell invasion. , 2005, Biochimie.

[38]  M. Björklund,et al.  Identification of a Negatively Charged Peptide Motif within the Catalytic Domain of Progelatinases That Mediates Binding to Leukocyte β2 Integrins* , 2003, Journal of Biological Chemistry.

[39]  C. Lynch Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. , 2011, Bone.

[40]  B. Sheu,et al.  A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.

[41]  P. Harari,et al.  Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.

[42]  M. Terol,et al.  Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. , 2008, Blood.

[43]  P. Ferdinandy,et al.  Matrix Metalloproteinase Inhibitors , 2010, Drugs.

[44]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[45]  G. Giannelli,et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.

[46]  A. Dufour,et al.  Role of Matrix Metalloproteinase-9 Dimers in Cell Migration , 2010, The Journal of Biological Chemistry.

[47]  S. Meroueh,et al.  Cell surface association of matrix metalloproteinase-9 (gelatinase B) , 2003, Cancer and Metastasis Reviews.

[48]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[49]  R. Fridman,et al.  Density‐dependent regulation of cell‐surface association of matrix metalloproteinase‐2 (MMP‐2) in breast‐carcinoma cells , 1998, International journal of cancer.

[50]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[51]  A. Dufour,et al.  Role of the hemopexin domain of matrix metalloproteinases in cell migration , 2008, Journal of cellular physiology.

[52]  R. Dwek,et al.  The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.

[53]  R. Cardiff,et al.  CD44v3,8–10 is involved in cytoskeleton‐mediated tumor cell migration and matrix metalloproteinase (MMP‐9) association in metastatic breast cancer cells , 1998 .

[54]  B. Marmer,et al.  Substrate Binding of Gelatinase B Induces Its Enzymatic Activity in the Presence of Intact Propeptide* , 2002, The Journal of Biological Chemistry.

[55]  P. E. Van den Steen,et al.  Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway* , 2009, The Journal of Biological Chemistry.

[56]  J. Becker,et al.  Coexpression of Integrin αvβ3 and Matrix Metalloproteinase-2 (MMP-2) Coincides with MMP-2 Activation: Correlation with Melanoma Progression , 2000 .

[57]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[58]  R. Sedláček,et al.  Matrix Metalloproteinase-19 Is Expressed in Myeloid Cells in an Adhesion-Dependent Manner and Associates with the Cell Surface1 , 2002, The Journal of Immunology.

[59]  Jingsong Xu,et al.  Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo , 2001, The Journal of cell biology.

[60]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[61]  W. Schiemann,et al.  Transforming growth factor-β and the hallmarks of cancer. , 2011, Cellular signalling.

[62]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[63]  C. Gahmberg,et al.  Intracellular and cell surface localization of a complex between alphaMbeta2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. , 2004, Journal of immunology.

[64]  J. Becker,et al.  Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. , 2000, The Journal of investigative dermatology.

[65]  A. Gaultier,et al.  The Hemopexin Domain of Matrix Metalloproteinase-9 Activates Cell Signaling and Promotes Migration of Schwann Cells by Binding to Low-Density Lipoprotein Receptor-Related Protein , 2008, The Journal of Neuroscience.

[66]  S. Weiss,et al.  A cancer cell metalloprotease triad regulates the basement membrane transmigration program. , 2006, Genes & development.

[67]  R. Fleischmajer,et al.  Tetracyclines: nonantibiotic properties and their clinical implications. , 2006, Journal of the American Academy of Dermatology.

[68]  J. Woodgett,et al.  IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. , 2006, Immunity.

[69]  Lisa S. Chen,et al.  Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. , 2010, Biochemical pharmacology.

[70]  A. Saven,et al.  Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Eck,et al.  The FERM domain: organizing the structure and function of FAK , 2010, Nature Reviews Molecular Cell Biology.

[72]  R. Bischoff,et al.  Physiology and pathophysiology of matrix metalloproteases , 2010, Amino Acids.

[73]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.

[74]  T. Salo,et al.  Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.

[75]  W. Kamps,et al.  The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. , 2004, Critical reviews in oncology/hematology.

[76]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[77]  A. Czirók,et al.  Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. , 2008, Molecular biology of the cell.

[78]  H. Nagase,et al.  MMPs Are IGFBP‐Degrading Proteinases: Implications for Cell Proliferation and Tissue Growth , 1999, Annals of the New York Academy of Sciences.

[79]  X. Wang,et al.  An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma , 2007, Oncogene.

[80]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[81]  R. Fridman,et al.  Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. , 1997, Cancer research.

[82]  P. Sharma,et al.  Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review. , 2011, Current medicinal chemistry.

[83]  Y. Ma,et al.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[84]  C. Overall,et al.  Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. , 2005, Cancer research.

[85]  L. Devy,et al.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies , 2010, Biochemistry research international.

[86]  T. Stricker,et al.  Pro-collagenase-1 (Matrix Metalloproteinase-1) Binds the α2β1 Integrin upon Release from Keratinocytes Migrating on Type I Collagen* , 2001, The Journal of Biological Chemistry.

[87]  J. Hohneker,et al.  Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. , 2003, Seminars in oncology.

[88]  D. Scadden,et al.  Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  I. Stamenkovic,et al.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.

[90]  D. Boger,et al.  Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[91]  D. Ruiter,et al.  Expression of integrin αvβ3 correlates with activation of membrane‐type matrix metalloproteinase‐1 (MT1‐MMP) and matrix metalloproteinase‐2 (MMP‐2) in human melanoma cells in vitro and in vivo , 2000 .

[92]  I. Sagi,et al.  Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? , 2010, Biochimica et biophysica acta.

[93]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[94]  Jin-Ao Duan,et al.  Selective matrix metalloproteinase inhibitors for cancer. , 2009, Current medicinal chemistry.

[95]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[96]  P. E. Van den Steen,et al.  Gelatinase B/matrix metalloproteinase‐9 cleaves interferon‐β and is a target for immunotherapy , 2003 .

[97]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[98]  Pedro Romero,et al.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.

[99]  A. Karsan,et al.  Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells , 2002, Cell Death and Differentiation.

[100]  P. E. Van den Steen,et al.  Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. , 2008, Biochemistry.

[101]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[102]  P. Bornstein,et al.  Extracellular Matrix Metalloproteinase 2 Levels Are Regulated by the Low Density Lipoprotein-related Scavenger Receptor and Thrombospondin 2* , 2001, The Journal of Biological Chemistry.

[103]  H. Nagase,et al.  Progress in matrix metalloproteinase research. , 2008, Molecular aspects of medicine.

[104]  M. Terol,et al.  Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. , 2010, Cancer cell.

[105]  J. S. Rao,et al.  Blockade of Tumor Growth Due to Matrix Metalloproteinase-9 Inhibition Is Mediated by Sequential Activation of β1-Integrin, ERK, and NF-κB* , 2008, Journal of Biological Chemistry.

[106]  A. Saven,et al.  Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[107]  J. Sparano,et al.  Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial , 2011, Cancer Chemotherapy and Pharmacology.

[108]  S. Rafii,et al.  A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. , 2008, Cancer cell.

[109]  M. Björklund,et al.  Gelatinase-mediated migration and invasion of cancer cells. , 2005, Biochimica et biophysica acta.

[110]  Y. Yano,et al.  Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. , 2007, British journal of clinical pharmacology.

[111]  W. Stetler-Stevenson,et al.  Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. , 1996, Cell.

[112]  C. Overall,et al.  Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.

[113]  Y. Okada,et al.  Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases , 2003, Oncogene.

[114]  R. Khokha,et al.  The Role of Tissue Inhibitors of Metalloproteinases in Tumorigenesis and Metastasis , 2008, Critical reviews in clinical laboratory sciences.

[115]  M. Björklund,et al.  Peptide Inhibition of Catalytic and Noncatalytic Activities of Matrix Metalloproteinase-9 Blocks Tumor Cell Migration and Invasion* , 2004, Journal of Biological Chemistry.